Furthermore, more CD163+CMAF+ than CD163+pSTAT1+ macrophages (ratio >1.5) were observed in 100% (40/40) of Th2-response group cases, in 60.6% (20/33) of EBV- cHL cases and in only 10.7% (3/28) of Th1-response group cases (P< 0.0005, X2) (Fig 3 and Table E in S1 File). This evidence concerns the gene MAF and classic Hodgkin lymphoma.